A new study suggests blockbuster weight loss drugs Wegovy and Zepbound are not cost-effective at their current prices, despite the proven health benefits. The study, published in JAMA Health Forum and ...

Eli Lilly has launched new 7.5 mg and 10 mg single-dose vials of Zepbound (tirzepatide), priced at $499 per month under the ...

Eli Lilly is expanding the supply and cutting the costs of its weight-loss drug Zepbound, broadening access to more patients without insurance. The company launched 7.5 mg and 10 mg vials of ...

Eli Lilly has lowered the price of its weight-loss drug Zepbound for patients paying out of pocket and introduced two new available vial doses.

(Reuters) -Telehealth firms Teladoc and LifeMD said on Thursday they had signed an agreement with Gifthealth, the pharmacy ...

The partnership comes as telehealth companies grapple with restrictions on the sale of some compounded GLP-1s.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Compounders had been allowed to produce and sell hundreds of thousands of their own versions of popular anti-obesity drugs.

Makers of the popular obesity treatments Wegovy and Zepbound are cutting prices for people without insurance. Danish ...

Danish drugmaker Novo Nordisk said Wednesday that it will drop prices 23% for all doses of Wegovy. The new monthly price of ...

Novo Nordisk A/S (NVO) has slashed prices for its blockbuster weight-loss drug Wegovy as competition in the obesity drug market heats up, with ...